Seasonal versus perennial immunotherapy: evaluation after three years of treatment.
We have performed a comparative study to evaluate seasonal and perennial schedules after 3 years of immunotherapy. Sixty patients suffering from rhinitis and/or asthma due to grass pollen sensitization were randomly allocated to receive a semi-depot extract of Phleum pratense according to a perennial or seasonal schedule. The last year of the study, 14 patients were recruited as a control group without immunotherapy. The cumulative dose was 602 BU in the perennial group and 372 BU in the seasonal group. The frequency and severity of side-effects were similar and very low in both treated groups. The IgE level was significantly lower after perennial immunotherapy at the end of the first 2 years. A seasonal decrease in specific IgG levels was observed in patients who interrupted immunotherapy, while this was not observed in patients under the perennial schedule. Symptoms and medication scores did not show differences between groups. Nevertheless, we found a significant difference between treated patients and the control group.
Muñoz Lejarazu
D
D
Department of Allergy, Hospital Santiago Apostol, Vitoria, Spain.
Bernaola
G
G
Fernández
E
E
Audícana
M
M
Ventas
P
P
Martín
S
S
Fernández de Corres
L
L
D000328:Adult; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000209:etiology / Q000628:therapy*; D007073:Immunoglobulin E / Q000097:blood; D007167:Immunotherapy; D008297:Male; D011058:Pollen / Q000276:immunology*; D012621:Seasons
D007073:Immunoglobulin E